Fagron Faces FDA Scrutiny Over Wichita Facility

Fagron SA (GB:0HNZ) has released an update.

Fagron received a warning letter from the FDA following a routine inspection at its Wichita facility, prompting the company to enhance its manufacturing processes. While most improvements have been addressed, Fagron is actively working with the FDA to resolve any remaining issues, and assures stakeholders of the quality and safety of its products. Despite the recall initiated in August, there has been no adverse impact on the business.

For further insights into GB:0HNZ stock, check out TipRanks’ Stock Analysis page.